| Autor: |
Unedo Hence Markus Sihombing, Andrijono Andrijono, Gatot Purwoto, Supriadi Gandamihardja, Alida R. Harahap, Primariadewi Rustamadji, Aria Kekalih, Retno Widyawati, Dzicky Rifqi Fuady |
| Rok vydání: |
2022 |
| DOI: |
10.21203/rs.3.rs-1459958/v2 |
| Popis: |
Ovarian cancer is one of the deadliest women’s cancers. There is much chemoresistance to ovarian cancer standard therapy. CD44+/CD24− have an essential role in developing chemoresistance and poor prognosis for the patients. We aimed to study CD44+/CD24− relationship with ovarian cancer chemoresistance and its ability to predict chemoresistance. This study is an ambispective cohort study of 32 people in each group at the Obstetrics-gynecology and pathology Department of Cipto Mangunkusumo, Tarakan, Dharmais, and Fatmawati Hospital. All suspected ovarian cancer patients will undergo cytoreductive debulking and histopathological examination. Chemotherapy will be given for six series followed by six months of observation. We determine therapy response with the RECIST Criteria (Response Criteria in Solid Tumours) then classify it into chemo-resistant or chemo-sensitive groups. Our study is the first study examining CD44+/CD24− in ovarian cancer from flow cytometry blood test and directly from ovarian cancer tissue by double immunohistochemistry. We found a significant relationship between increased levels of CD44+/CD24− expression (p +/CD24− was significantly associated with ovarian cancer chemoresistance and CD44+/CD24− immunohistochemistry is a better predictor. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
